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1. INTRODUCTION AND FOCUS
OF THE PAPER
Political controversy on the prices
of patented medicine, particularly in 
relation to the HIV/AIDS pandemic in 
many parts of the African continent, has 
raised debate on the impact of 
intellectual property rights (IPR) in 
developing countries. It is argued that 
IPR legislation, by maintaining high 
price levels, renders drug treatment 
beyond the means of the masses, of the 
poor and most needy. Therefore IPR is  
seen as a form of political and socio-
economic discrimination (Denny, 
2001).  
In response to political and public 
outcry, many international pharmaceu-
tical corporations have felt morally 
obliged to lower the cost of expensive 
drug treatments. This is unlikely to 
become a permanent strategy as 
revenue and profits expectations often 
come from new drugs, which have 
undergone a costly and prolonged 
process of R&D before reaching 
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the marketplace.  As a long-term 
strategy, however, international 
corporations and market globalization 
demands that an enforceable legal 
framework protecting intellectual 
property becomes a normal part of 
business activity.  
One of the most prominent IPR 
legal frameworks is the TRIPS (Trade 
Related Aspects on Intellectual 
Property Rights) Agreement, a pre-
condition for membership of the World 
Trade Organization (WTO).  TRIPS is a 
far-reaching international agreement on 
minimum standards for IPR to protect 
patents, trade secrets, copyrights and 
trademarks (Jorda, 1999).  Countries 
that have signed the agreement are 
committed to comply with legally 
defined standards within a fixed time. 
Under the agreement, developing 
countries needed to have complied by 
the year 2000 (including Indonesia). 
The least developing nations still have 
time to comply until the year 2005 
(Sherwood, 1990).  
Whatever the merits of the political 
and moral debate, from a business 
standpoint attention is primarily 
focused on the economic consequences 
of IPR in developing countries. There 
are two camps of thought. One argues 
that the stimulus effect on their 
economies is limited, mainly because of 
under-developed conditions, such as 
low levels of advanced work-related 
knowledge and skills and an inadequate 
technology infrastructure. In this 
argument, IPR legislation makes little 
economic difference (Sayeed, 1995). 
The opposite camp argues that IPR 
legislation has positive, mostly longer-
term, impact on overall economic 
prosperity, notably through increased 
capital investment, technology 
innovation and knowledge transfer 
(Bale, 1999; Rappe/Rozek, 1990; 
PhRMA, 1996).  
This paper aims to provide further 
conceptual understanding of the role of 
IPR, notably in terms of economic 
effects. It examines the perceived 
relationship between patent protection 
(as a key element of IPR) and economic 
effects from the perspective of leaders 
and decision-makers (CEOs and other 
senior managers) in the international 
pharmaceutical industry located in 
Indonesia.  In reality, it would be 
virtually impossible for industry leaders 
to ignore the importance of the TRIPS-
agreement and the long-term 
consequences of having an established 
legal and regulatory framework 
protecting intellectual property, for it 
lies at the heart of the global 
pharmaceutical industry.  In that sense 
the impact of the TRIPS agreement may 
be regarded as a catalyst for strategic 
thinking within the industry and change 
in Indonesia. The underlying 
assumption is that industry leaders 
would naturally regard TRIPS and IPR 
legislation as an opportunity to increase 
revenue and profit expectations.  In this 
paper the idea of economic effects 
widens to include future capital 
investment, knowledge and technology 
transfer, along with other economic 
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effects that provide the sustainability 
for an industry that operates on a long-
term basis. 
The Indonesian context is valuable 
because other developing countries 
seeking membership of the WTO would 
have to undertake the same process of 
compliance with the TRIPS agreement 
and the consequent changes this usually 
brings to traditional cultural and 
business practices, where IPR has 
largely been ignored. 
An overview of the economic effects 
of patent protection 
A meta-analysis of the commercial 
value of internationally patented 
products was performed using market 
statistics (IMS-ITMA, 2/1998), to scope 
the economic dimension of the topic, 
that is, the sales volume of 
internationally patented drugs in 
Indonesia. Even though the TRIPS 
Agreement does not cover an 
immediate acknowledgement of 
international patents (only additional 
pipeline protection would), this analysis 
seemed likely to provide ideas 
regarding the economic dimension of 
TRIPS after implementation.  
In view of a global R&D cycle 
time of 10–12 years (DG Bank, 1999) 
and an average global patent protection 
of 20 years after the first application 
and an average regulatory cycle time of 
at least one year, the theoretical average 
span for exploiting a patent would be 
fewer than 10 years in Indonesia. 
Therefore, products were divided into 
two groups: those that had been on the 
market more than 10 years and those 
for fewer. As depicted in figure 1, in 
1998 approximately 70% of the 
Indonesian market was captured by 
products on the market longer than 10 
years. The IMS-ITMA data on launch 
dates were used for this analysis. 
Products on the market for 10 years or 
fewer contributed approximately 30% 
of the total market (RP 1,403 Bio.). 
A further iteration was introduced, 
to value the overall significance of 
patentable products based on the 
international patent status. This analysis 
was important to evaluate the potential 
impact on the local pharmaceutical 
industry which was of particular 
concern to the Indonesian government. 
The market segment of products 
launched by international companies 
over the previous ten years was 
analyzed, to see if these items would 
still be internationally patentable, that is 
to say, patentable using their 
international patent term. The key 
selection criterion for this additional 
step was sales of these products 
launched over the previous 10 years by 
two leading generic companies (Cox 
and Ratiopharm) in Europe. It can be 
assumed that these generic firms launch 
generics soon after the patent expiry of 
the original product, so this was 
considered a pragmatic approach to 
reach approximate findings. Moreover, 
due to the internationalization of patent 
systems and the harmonization of 
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patent duration between the US and 
Europe, this seemed to provide 
ent grounds for approximation. 
Indonesia before its official 
compliance with TRIPS in 2000 
provided an ideal opportunity to sufficiThe overall error margin was 
considered acceptable, due to the 
overall efficiency of generic 
manufacturers, thanks to the BOLAR 
provision (Correa, 1999). 
It was found that no more than 
14% of the total market would be in the 
category ‘internationally patentable’ — 
6.7% of market commercialized by 
local companies (PMDN) plus 7.3% of 
the market commercialized by 
international companies (PMA). These 
findings were broadly in line with a 
study in India (Redwood, 1995).  
examine in some depth the economic 
consequences of new legislation 
protecting intellectual property, in an 
industry characterized by the added-
value placed on knowledge and 
technology as the basis of product 
innovation. A knowledge gap and the 
necessity for further research in 
developing countries has been 
identified by previous research 
(Sherwood, 1997). The aim of this 
paper is to add to information and to 
interpretation. 
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Pharmaceutical Market in Indonesia
(IMS – ITMA 2/1998, Moving Annual Total)
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less than 10 years ago
Figure 1 
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Adopting a business position, the 
paper focuses on qualifying and 
evaluating the expected (or at least 
potential) economic effects of new IPR 
legislation on the pharmaceutical 
industry in Indonesia arising from 
the TRIPS agreement. As explained, 
the research-based evidence is drawn 
from the perceptions and 
interpretations of decision-makers of 
the international pharmaceutical 
corporations in Indonesia. They were 
asked to think about the impending 
IPR legal framework in related ways. 
First, they had to generally consider to 
what extent they regarded IPR 
(confined to patent protection) as a 
change catalyst and driver in the 
industry in Indonesia. Second, they 
were asked to think about the interplay 
between patent protection and other 
well-recognised change drivers in 
the industry and assess the relative 
importance of IPR. Although the 
main emphasis of this paper is on 
economic and business aspects, it is 
necessary to take account of 
perceptions of IPR as a catalyst for 
change and its interaction with other 
industry drivers.  
2 RESEARCH DESIGN AND 
METHODS
The fieldwork research was 
conducted in 1999, one year before the 
process of establishing a legal 
framework for IPR was to officially 
begin. The research design was based 
on a consultative process with industry 
leaders. Their perceptions and 
intentions were considered as the 
measurable outcomes, reported in the 
data-set findings later in this article. 
Thought was given to the nature and 
admissibility of evidence in this 
interpretive as well as empirical study. 
It was believed that as the industry 
leaders were experienced and 
knowledgeable senior executives, their 
perceptions and interpretations about 
the future implications of IPR would 
be acceptable evidence. All had 
major managerial responsibilities and 
were used to considering environ-
mental developments. Pragma-
tically, the industry leaders were 
driven to exploit commercial 
opportunities emerging from 
environmental changes. An-
ticipating the future was crucial for 
them. It was further assumed that 
if TRIPS was not perceived as 
important, it was unlikely to have 
economic consequences. This 
thinking is in line with a well-
established tradition of scholarship 
in this field of research 
(Mansfield,1994). With a few 
exceptions, members of the peak 
body in Indonesia, the Inter-
national Pharmaceutical Manu-
facturers Group (IPMG), agreed that 
TRIPS was at least a potential 
catalyst for change and develop-
ment in the country and 
therefore worthy of study. Therefore 
IPMG’s support was given for the 
research that comprises this paper.  
The primary knowledge rests on 
the subjective perceptions, intents, 
experiences and reflections of a number 
of people intimately involved in the 
pharmaceutical industry in Indonesia, 
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as CEOs, managers, legal experts, 
physicians and others with considerable 
inside knowledge. 
The research had some obvious and 
unavoidable limitations. First, it was 
confined to the international
pharmaceutical industry, due to an 
inherent conflict of interest for local 
pharmaceutical companies. Local 
pharmaceutical companies had the most 
to lose from the changes, as for many 
years they had freely copied the 
products of the international
corporations. Second, the research 
could only be a single opportunity. A 
longitudinal study would have been 
desirable, to determine to what extent 
the predictions of industry leaders were 
realized, but this was not possible given 
the necessary time span and the many 
factors — particularly political and 
social unrest — driving decisions. 
These uncertainties need to be 
considered when evaluating the 
research results. 
In order to strengthen the reliability 
of results, a number of research devices 
were used. The data collection was 
primarily based on a membership 
survey and focus group discussions 
with the IPMG executive committee. 
Further evidence was obtained from an 
intensive case study of a major 
pharmaceutical corporation, a market 
research survey of medical practitioners 
and interviews with key government 
officials.  
3 RESEARCH SAMPLE
The IPMG group represented 
around 50% of the Indonesian 
pharmaceutical market (IMS, 1999) 
and their global organizations of 
IPMG companies contributed 54% 
of total world market sales as well 
as around 78% of worldwide 
spending in pharmaceutical R&D 
in 1999 (see figure 2). Among the 
IPMG companies were 24 of the 
leading 30 pharmaceutical 
manufacturers in the world (IPMG 
Open Sales Exchange Report, July 
1999; Script, 1999). 
Furthermore, on the basis of 
background research, this sample 
population represented one of the 
largest collections of informed 
opinion in the pharmaceutical industry 
to reflect on the strategic and 
change-management implications of 
IPR legislation, at least in Indonesia. 
The nearest comparable study (Lee, 
1994), while addressing the issue of 
IPR, had a larger sample but had only 
nine firms from the chemical 
industry/pharmaceutical firms. The 
cited Mansfield study represented a 
smaller sample of chemical and 
pharmaceutical companies (Mansfield, 
1994). 
4  DATASET FINDINGS
In the first set of findings 
the nature of evidence is based 
on perceptions of what CEOs and 
senior managers think is emerging 
in  the  industry  as  a   consequence  of 
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anticipated changes to patent protection 
laws in the country. Their ideas about 
strategic options are based on these 
perceptions, regarded as admissible 
evidence in the article. The findings 
suggest that IPR (in particular, patent 
protection) in accord with TRIPS will 
be a catalyst for more foreign direct 
investment, technology transfer, 
knowledge spillovers, strategic 
alliances, innovative activities and 
economic benefits, for the research-
based pharmaceutical industry of 
Indonesia and the country generally. An 
important finding relates to the time 
factor. It was agreed that the expected 
effects would take some years to make 
a significant difference, as in the long- 
time horizon of the pharmaceutical 
industry generally.  
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Figure 2 : Sources: IMS/ITMA 98; IPMG Open Sales Exchange, Script 1999 
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5  IMPORTANCE OF IPR AS A  
CHANGE DRIVER 
To understand the importance of 
IPR as a change driver, a survey was 
done on the CEOs of the IPMG 
companies. Twenty-five of 35 
pharmaceutical companies responded to 
a number of questions. The findings 
were triangulated with two additional 
focus group interviews involving senior 
executives of the industry. IPR or the 
TRIPS Agreement has been confirmed 
as an important change driver for the 
pharmaceutical industry in Indonesia 
across all research items. IPR scored 
highly in terms of importance compared 
with industry-related change drivers 
and macro-level key factors. The key 
factors that came to the minds of 
country managers are in table 1.  
Change Drivers for the International Pharmaceutical Industry in Indonesia 
Industry Related Factors Macro Drivers 
Innovation Free Trade Zone (ASEAN) 
Scientific Know How  GDP Development 
Profit and Revenue Expectations Exchange Rate 
Investment Inflation 
Industry’s competitiveness Emerging Middle Class 
Alliances National Reimbursement 
Regulatory Process Managed Care 
Mergers and Acquisition Law Enforcement 
Down Sizing Factor Conditions 
Generics Exportations 
Positive List IPR 
Counterfeit Products 
Code of Conduct 
Table 1 
IPR was consistently mentioned as 
one of the most important change 
drivers  during  the  various  focus 
group interviews which complemented 
the survey. These focus group 
interviews involved CEOs of a number 
of international pharmaceutical 
manufacturers  in  Indonesia  as  well as 
senior managers of a case study 
company (a leading international 
pharmaceutical company in Indonesia. 
In a survey with international 
pharmaceutical companies supported by 
their association (IPMG), CEOs 
considered that a major portion of their 
future business (average of 54%) would 
be affected by IPR in the long-term —
 confirming the importance of IPR as a 
change driver. During the matrix 
evaluations by the CEOs and the case-
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study company, IPR ranked third and 
second as an active driver for change. 
igh consistency of results shows 
pharmaceutical industry. 
The results — figure 4 — clearly The h
that IPR is an important change driver 
for the research-based pharmaceutical 
industry and indicates reasonably 
reliable research results. 
IPR appeared to be a longitudinal 
change driver, having a long time 
horizon, until it could unfold its 
complete effect on other change drivers, 
in  a  context   such  as   the  Indonesian  
demonstrate the long-term effect of IPR 
in various key aspects. It becomes 
evident that the number of skeptical 
opinions towards the effects of IPR 
diminishes over time, while the 
expectations towards profit and 
revenues increase. Moreover, some 
(11%) can envisage investment in R&D 
activities in the long-term. 
Industry Survey IPMG Companies
Increase of Revenues, IPMG Co. (39% of respondents)
%
10 20 30 40
Improvement of Indonesia’s Image Internationally (11%)
Initiation of R&D Projects (11%)
Improvement of Profitability for International Co. (11%)
Increase of Scientific Promotion (6%)
Initiation of Alliances (6%)
Transfer of Knowledge (6%)
Acceleration of New Product Introductions (6%)
No impact (6%)
Long-term impacts (beyond 5 years) expected due to the TRIPS Agreement in Indonesia
Figure 3 
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Perceived Impact of Patent Protection Over Time after the Introd uction of TRIPS
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6  INTERACTIONS OF IPR WITH 
OTHER CHANGE DRIVER 
To understand IPR’s potential 
areas of influence from a high-level 
perspective, influence matrices were 
developed based on the results of two 
focus group discussions with senior 
executives of international 
pharmaceutical companies in Indonesia. 
The factors analyzed are depicted 
below: 
Innovation Investment       Profit/Revenue  
Expectation 
Scientific Know How     Phase III Trial       Alliances 
Industry’s Competitiveness        Set up new functions 
Table 2 
During the focus group interviews, 
interdependencies of key industry 
drivers were discussed and evaluated 
with CEOs of leading pharmaceutical 
companies of the IPMG. IPR had one of 
the most active parameters 
(score = 151) next to innovation (156), 
scientific know-how (152), and profit 
and revenue expectations (151). A total 
score of 120 would have been 
considered a neutral one. All other 
factors scored significantly fewer.  
Ranking of Parameters according to their 
total active score 
1. Innovation 156 
2. Scientific  Know How 152 
3. Profit and  Revenue Expectations        151 
4. IPR 151 
Average Score of Parameters              140 
Table 3 
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This pattern is supported by the 
second workshop findings with senior 
managers of a case-study company. IPR 
had a particularly strongly perceived 
influence on investment and innovation. 
Also strongly perceived were the 
influences on profit and revenue 
expectations, set-up of new functions, 
set-up of Phase III trials, scientific 
know-how and alliances. IPR was 
evaluated with a passive score of 141 
— in line with the average of all factors 
evaluated (140). As participants of the 
focus group interviews considered the 
factors “companies’ international 
competitiveness” and “set-up of new 
functions” as less relevant, they were 
not considered in the following 
mappings. During the focus group 
interviews the discussion centered on 
IPR as an active driver and the time 
horizon of its influences. Participants 
concluded that only one influence 
would have a noticeable impact with a 
time horizon of less than two years. 
This was the initial impact on revenue 
expectations, investment and Phase III 
trials. Revenue expectations had 
already had a perceived impact on 
investment. Thus the initial one on 
investment was only indirect. The 
evaluation on time horizons by the 
participants has been largely confirmed 
by the evaluation of additional survey 
results (see figure 5).  
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Participants were asked also to 
consider how the network would 
change with a medium-term time 
horizon (2–5 years). As depicted in 
figure 6 the direct influence on revenue 
expectations and alliances and Phase III 
trials was valued more strongly 
compared to the short-term perspective. 
The interplay between investment and 
revenue expectation was perceived very 
strongly. Furthermore, alliances seem to 
have a strong impact on investment 
decisions. This medium-term evaluation 
is supported by the survey results 
(questions: 3, 4, 6). 
Taking a longer-term perspective 
(longer than 5 years) participants 
considered the matrix finding 
applicable. This evaluation of the main 
drivers is depicted in figure 6. The main 
influences are on investment and 
innovation. The impacts perceived on 
profit and revenue expectations, set-up 
of new functions, set-up of Phase III 
trials, scientific know-how and 
alliances were noticeable. 
Due to the strong interconnection 
of the key drivers, the overall system 
appeared to reinforce itself and to 
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strengthen the impacts of a factor such 
as IPR on other key drivers. This might 
snowball effect. However, it 
7  IMPLICATIONS OF IPR ON 
INVESTMENTS be a  
became clear that it needed some time 
to display its full significance.  
The mappings depicted above 
reflect the perceptions of a small 
number of country managers (n=5) of 
international pharmaceutical companies 
and are therefore more indicative than 
factual evidence. However, the results 
are supported by a survey conducted 
with the member companies of the 
International Pharmaceutical
Manufacturer Group (IPMG) in 
Indonesia (n=35).  
The economic dimensions of the 
internationally patented products in 
Indonesia need to be kept in mind 
before turning to more precise 
perceptions and intents of country 
CEOs regarding investment decisions 
driven by IPR. In the case of TRIPS 
implementation, the additional 
economic potential refers only to the 
patented products under Indonesian 
jurisdiction. As mentioned, the 
economic potential of these products 
represents less than 2% of the entire 
market.  CEOs mentioned that 
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international pharmaceutical companies 
could not fully capitalize on this 
potential, as with their sales operation 
and their pricing structure they could 
not reach low-income groups. They 
believed that they could access around 
20% of the sales of local companies 
with these items. Thus the expected 
immediate accessible potential due to 
TRIPS could be less than 1% of the 
entire market. 
These relatively small additional 
market potentials might explain why 
CEOs and other senior executives 
foresaw that it would take several years 
for major impacts driven by the 
implementation and enforcement of 
IPR. The current dimensions at stake 
(in US$) did not suggest an immediate 
rethinking of the role of Indonesia by 
multinational pharmaceutical 
companies in their global strategies. 
The analysis helped to understand why 
companies foreshadowed investment 
primarily in marketing and sales during 
the first phase. 
As outlined, TRIPS supported an 
increase in revenue expectations for the 
original brand, due to the temporary 
period of exclusivity, but would be, 
according to the discussions with 
CEOs, limited to an additional potential 
of around 20% of the status quo, due to 
purchasing-power limitations and the 
current desire of higher-income groups 
to purchase international, original drugs 
in any event. Thus, strategic alliances 
with local companies appeared to 
provide an interesting commercial 
opportunity to allow the international 
company to reach additional customer 
groups by different pricing and a 
complementary sales organization. The 
main areas for strategic alliances 
identified ranged from co-marketing 
agreements until the acquisition of a 
local company. Cooperation in product 
development and distribution appeared 
less likely.  
In order to quantify IPR’s potential 
impact on investment in the research 
context, IPMG members were asked to 
consider what specific advice they 
might give the head offices of their 
respective companies regarding 
investment, prompted by the 
establishment of patent protection in the 
country. Of course, the estimates were 
no more than that, and were intended to 
reflect a degree of confidence in the 
Indonesian context. CEOs were asked – 
“Assuming that patent protection will 
be implemented and enforced, what 
recommendation might you make to 
your head office regarding future 
additional investment activities within 
a period of 5 years?” 
         (1)         (2) 
 No Below US$0.5 million 
  (3)        (4) 
    < US$1 million > US$ 1 Mio.
A total of 63% of the IPMG 
companies (n = 22) responded to this 
question. The frequencies tables are 
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split into the respective categories RD = 
Research and Development; CT = 
Clinical Trials; PROD = Production; 
MANUF = Manufacturing; MARK = 
Marketing and LOGIST = Logistics. 
The following results were found: 
With regard to the field of R&D, 
64% of all respondents thought that 
there would be no additional investment 
due to the emergence of 
implementation and enforcement of 
patent protection over a period of five 
years. A total of 91% of all respondents 
were of the opinion that the additional 
investment would be below US$0.5 
million within five years. 
In the area of Clinical 
Development, 23% of the respondents 
believed that there would be no 
additional investment due to the 
emergence of implementation and 
enforcement of patent protection in 
R&D over a period of five years. A 
total of 64% of all respondents were of 
the opinion that the additional 
investment would be below US$0.5 
million within five years while 36% of 
all respondents could imagine 
additional investment of more than that.  
Research and development 
Frequency Percent Valid  
percent 
Cumulative  
percent 
.00 2 9.1 9.1 9.1
1.00 12 54.5 54.5 63.6
2.00 6 27.3 27.3 90.0
3.00 2 9.1 9.1 100.0
Total 22 100.0 100.0
Table 4 
Clinical development 
Frequency Percent Valid   
percent 
Cumulative  
percent 
.00 1 4.5 4.5 4.5
1.00 4 18.2 18.2 22.7
2.00 9 40.9 40.9 63.6
3.00 7 31.8 31.8 95.5
4.00 1 4.5 4.5 100.0
Total 22 100.0 100.0
Table 5 
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With regard to Production, 46% 
believed that there would be no 
additional investment due to the 
emergence of implementation and 
enforcement of patent protection in the 
area of R&D over a period of five 
years; 64% thought that the additional 
investment would be below US$0.5 
million within five years while 36% 
could imagine additional investment of 
more than that.  
Production 
Frequency Per cent Valid  per 
cent 
Cumulative per 
cent 
.00 2 9.1 9.1 9.1
1.0 8 36.4 36.4 45.5
2.0 4 18.2 18.2 63.6
3.0 6 27.3 27.3 90.9
4.0 2 9.1 9.1 100
Tot 22 100.0 100.0
Table 6 
In the area of Manufacturing, 
36% of all respondents believed that 
there would be no additional investment 
due to the emergence of 
implementation and enforcement of 
patent protection in  R&D over a period  
of five years. A total of 50% of all 
respondents were of the opinion that the 
additional investment would be below 
US$0.5 million within five years while 
50% of all respondents could imagine 
additional investment of more than that. 
Manufacturing 
Frequency Per cent Valid  per 
cent 
Cumulative per 
cent 
1.00 8 36.4 36.4 36.4
2.00 3 13.6 13.6 50.0
3.00 7 31.8 31.8 81.8
4.00 4 18.2 18.2 100.0
Total 22 100.0 100.0
Table 7 
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With regard to Marketing, 32% of 
the  respondents  believed  that  there 
would be no additional investment 
induced due to the emergence of 
implementation   and   enforcement    of  
patent protection in R&D over a period 
of five years. However, 68% of all 
respondents were of the opinion that the 
additional investment would be above 
US$0.5 million within five years. 
Marketing 
Frequency Percent Valid
per cent 
Cumulative 
per cent 
.00 1 4.5 4.5 4.5
1.0 1 4.5 4.5 9.1
2.0 5 22.7 22.7 31.8
3.0 7 31.8 31.8 63.6
4.0 8 36.4 36.4 100.0
Tot 22 100.0 100.0
Table 8 
In logistics, 32% believed that 
there would be no additional investment 
due to the emergence of 
implementation and enforcement of 
patent protection in R&D over a period 
of five years. A total of  77%  of all 
respondents were of  
the opinion that the additional 
investment would be below US$0.5 
million within five years while 23% of 
all respondents could imagine 
additional investment of more than that. 
Logistics 
Frequency Percent Valid
percent 
Cumulative  
percent 
.00 1 4.5 4.5 4.5
1.00 6 27.3 27.3 31.8
2.00 10 45.5 45.5 77.3
3.00 3 13.6 13.6 90.9
4.00 2 9.1 9.1 100.0
Total 22 100.0 100.0
50
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In table 10 the mean values and standard deviation underpin the results from the 
findings of the frequencies. 
Mean Standard deviation Sum
RD 1.36 .79 30.00
CT 2.14 .94 47.00
PROD 1.91 1.19 51.00
MANUF 2.32 1.17 51.00
MARK 2.91 1.11 64.00
LOGIST 1.95 1.00 43.00
Table 10 
The highest score was reached in 
the area of Marketing and Sales 
(2.91) — an average additional 
investment between US$0.5 million and 
$1.0 million due to the introduction of 
patent protection over five years. This 
appeared to be influenced by the 
companies’ global strategies that 
usually emphasized the optimization of 
commercialization process for 
Indonesian subsidiaries. The second 
highest score was reached by 
manufacturing. As demonstrated, most 
international pharmaceutical companies 
performed manufacturing operations in 
Indonesia. The score of Manufacturing 
of 2.32 meant an average additional 
investment of above US$0.5 million. 
In clinical trials, the third highest 
score (2.14) was reached — an average 
additional investment of less than 
US$0.5 million over five years. The 
substantial standard deviations per 
value  reflected  a  considerable  spread 
of evaluations which could be related to  
different perspectives on the role of the 
respective Indonesian subsidiaries in 
the global strategies of pharmaceutical 
corporations, as well as the different 
levels of confidence in the available 
factor conditions and prospects. 
Overall, the trends confirmed the 
qualitative results of the workshops 
with CEOs and senior management of 
the case-study company. 
Five key parameters primarily 
drove investment decisions according to 
the perceptions of CEOs participating 
in workshop 2: Net Present Value, 
Factor Conditions, Global Strategy, 
Innovation and IPR. Global strategy 
relates to the fact that every company 
had a distinct perspective regarding the 
role of Indonesia in their country 
portfolio.  
According to capital-market 
theory, investments are pursued when 
the net present value (NPV) of an 
investment is positive. Therefore, it is 
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important to understand the factors 
driving net present value at this stage. A 
recollection of the definition provides 
deeper insights. NPV is defined as the 
risk-adjusted discounted future cash 
flows of an investment (Brealey & 
Myers, 1991). This means that the 
future income stream, and the cost of 
capital and risk, determine the net 
worth of an investment project and the 
subsequent level of investment. The 
inappropriate protection of intellectual 
property and unethical business 
practices represent additional risk that 
reduces the anticipated value of a 
project. Consequently, willingness to 
invest is impaired. Therefore, IPR is 
considered to have an important role in 
this context. 
The participants saw Indonesia’s 
role more as an interesting market for  
the future, due to the large population 
and the expected economic growth.   
Net present value is driven by two 
dimensions: risk and future revenue 
expectations. Both were positively 
influenced by IPR. The opportunity for 
additional revenues and improved legal 
security (meaning the reduction of risk) 
appears to explain the prominent 
pivotal role of IPR in the research-
based pharmaceutical industry. In 
industries with long time horizons, such 
as the pharmaceutical industry, risk is 
an important component when 
appropriating resources. IPR does not 
abolish risk but seems to reduce risk for 
future investment decisions for 
international pharmaceutical companies 
in Indonesia, based on the findings of 
this research.  
 
NPV
Level of
IPR
Interplay between IPR and NPV
Risk
Future
Revenues
Figure 8 
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9 OTHER LIKELY IMPLICATIONS 
OF IPR 
IPR’s impact on alliances and 
technology transfer are considered as 
additional benefits of compliance with 
international IPR-standards for 
developing countries.  
In discussions with senior 
executives, the concept of technology 
transfer and the formation of alliances 
were considered as likely outcomes of 
compliance with the TRIPS agreement in 
Indonesia. To generate a better 
understanding and a broader basis of 
informed opinions about this topic, 
questions were designed within the  
frame of the survey with IPMG  
companies. Another stimulus effect of  
patent protection is its possible role in  
encouraging alliances, not directly, but  
rather as one factor indirectly 
influencing the process. The question 
hints at strategic alliances between the 
international and local pharmaceutical 
companies. This follows the implicit 
idea that the inception of IPR laws and 
regulations arising from the TRIPS 
Agreement would, sooner or later, 
weaken the market position of local 
companies. To improve their prospects, 
they would need to consider forming 
strategic alliances between themselves 
or with the much stronger international 
companies. Moreover, these would also 
open opportunities for international 
companies. The question that follows 
addresses this, as perceived by 
members of the IPMG. A clear majority 
(74% of respondents) thought that 
patent protection stimulated strategic 
alliances, although a timeframe was not 
provided for members to formulate 
more refined answers.  
%
%
% of Respondents
that foresee alliances
to emerge
Perceived Impact of Patent Protection on the Formation of Alliances
Industry Survey IPMG Companies
% of Respondents
that do not  foresee 
alliances to emerge
%
Marketing
( %)
Product Development
/ R&D  ( %)
Manufacturing
( %)
Distribution
( %)
Areas of Alliances
Figure 9 
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It seems that the highest potential 
benefits for international companies can 
be reaped from alliances with local 
companies in the marketing and sales 
area. The most far-reaching alliance 
would be the acquisition of a local 
company. But they were invited to 
consider in what areas of industry 
activity such strategic alliances were 
likely to occur (see below). The 
findings suggested that alliances and 
collaboration were more likely in the 
marketing (45% of responses) and 
distribution (15% of responses) areas, 
where local knowledge and ‘inside’ 
connection was an advantage, than in 
technology areas such as R&D, where 
international standards might not be 
reached by local companies. The 
reasons for these answers are likely to 
relate to the prevalent skepticism 
towards a sound implementation of the 
TRIPS Agreement as well as towards 
the TRIPS Agreement itself. As 
previously mentioned, TRIPS does 
mean the highest IPR standards and is 
likely to encourage economic activities 
to a level of manufacturing but not 
necessarily to R&D (Sherwood, 1997).  
These findings are supported by the 
fact that after the period of exclusivity 
for patented products, large customer 
groups might not be reached for new 
compounds, as they cannot be reached 
by multinational companies (either due 
to limited organization size or to the 
inability of lower-income groups to pay 
for products). Cooperation with local 
companies would allow international 
companies to achieve a wider reach 
and/or to differentiate prices. 
Once more, a minority of IPMG 
members (a total of 5 replies) was of 
the view that strategic alliances were 
unlikely to emerge after the year 2000. 
Four out of the five replies suggested 
that the interests of international 
companies were insufficiently served. 
Another question in the industry 
survey dealt with IPR’s potential 
impact on technology transfer. A key 
aspect of many innovation-driven 
industries such as the pharmaceutical 
industry is its reliance on advanced 
technology (directly related to 
knowledge and innovation formation) 
to develop new products. The question 
arises, whether patent protection, once 
established in Indonesia after the year 
2000, would transfer technology and 
encourage technology development in 
locally based companies and 
institutions, in effect adding value to 
their overall contribution. The overall 
factor conditions of Indonesia are likely 
to be enhanced through this kind of 
economic activity. These transfers 
might support productivity gains. 
A clear majority of 81% of 
respondents (17 out of 21) were of the 
opinion that technology transfer was 
more likely as a consequence of patent 
protection. The views of the four with 
reservations follow shortly, after the 
presentation of the next question, which 
identifies those areas of industry 
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activity most likely to reap the benefits 
of technology transfer. 
 
 
 
M
%
100
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50
25
0
81%
% of Respondents
that foresee technology
transfer
Perceived Impact of Patent Protection (according to TRIPS) on Technology Transfer
Industry Survey IPMG Companies
% of Respondents
that do not  foresee 
technology transfer
19%
Manufacturing
(45%)
Clinical Development
(22%)
anagement
(4%)
Marketing
(17%)
Areas of Technology Transfer
Internationalization
(4%)
IT  
(4%)
Figure 10 
Technology transfer was most 
likely in manufacturing (48%) and 
clinical development (22%). No impact 
was detected in terms of basic research. 
These responses reflected the fact that 
technology transfer was directly related 
to these areas of activity. Out of the 
four negative replies, two respondents 
referred to a lack of competence and 
missing trade-secret regulations.  
9 Discussion of the key findings  
The research findings were 
intended to shed light on IPR’s role as a 
change driver, the importance of the 
time factor for its effects, its potential 
implications on investment, and its 
potential implications on other 
economic areas such as technology 
transfer and alliances. 
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Primary emphasis has been placed 
on IPR’s critical impact on investment 
decisions. According to Sherwood, 
robust intellectual-property protection 
can be expected to produce maximum 
benefits in markets where private 
capital and open trade are encouraged 
(Sherwood, 1997, p. 492). Even though 
the comparisons below are tentative, 
they provide a rough picture of how to 
evaluate TRIPS in comparison with 
other IPR systems distinguished by 
robustness (Sherwood, 1997a, p. 496).
 Comparison of Intellectual Property Systems 
S)
 tio
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 riv
 ltur
 
ria
bly
sk 
 sity
Trade- Investment-
Non-Robust Enhancing Stimulating
Systems Systems (TRIP Systems
innova n is random/sporatic innovation in some areas achieved innovation is planned and constant
low pr s of some priated products higher prices for those products prices lower than trade model
little pr rietary technology acqu. some proprietary technology acqu. more proprietary knowledge acqu.
limited man skill development some human skill development higher skills developed
little p ate investment in technology private investment in low technology private investment in high technology
agricu al base - old science agricultural base - some new science agricultural base - best new science
indust l base - sales/distribution industrial base - some pirates displaced industrial base - new high tech 
assem by imports industries sprin up
little ri capital some risk capital optimum risk capital
univer  technology, theoretical unused some university technology transfer more university technology transfer
Sherwood, 1997b 
Table 11 
In a different analysis, Sherwood 
studied the IPR system of mostly Latin 
American countries and rated them on a 
scale from 0 to 100 from an investor’s 
perspective (Sherwood, 1997b). 
Sherwood invoked Mansfield’s 
correlation between investment and IP 
protection from his World Bank report 
(Mansfield, 1995), indicating that the 
TRIPS  level  of   protection  was  good  
enough to support private investment 
only in sales, distribution, assembly, 
and parts of manufacture. Only higher 
levels of protection encouraged 
complete manufacture or research and 
development. Even though the analysis 
provided only broad indications, it gave 
important trends in the discussion on 
IPR. 
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(Sherwood, 1997 b)
Impact of IPR on Stimulation of Investment
Figure 11 
TRIPS is likely to provide 
sufficient protection to encourage the 
willing transfer of certain technology. A 
minimum threshold in protection must 
be achieved to encourage local 
companies to invest sufficiently in 
training and internal research and 
development of products and processes. 
Even though levels of investment and 
technology transfer are very sensitive to 
levels of IPR protection (Mansfield, 
1994; Mansfield, 1995), the stimulus of 
intellectual property to investment is 
not perfect nor is it linear. The level of 
TRIPS protection needed to reach that 
threshold still needs to be explored. 
According to Sherwood, the impact of 
the TRIPS Agreement on most 
developing countries is likely to be 
slightly negative in the short run (one to 
two years) and increasingly favorable 
as the mindsets of local firms and 
individuals change and they realize the 
potential benefits (Sherwood, 1997).  
Indonesia would be likely to score 
40–50 before compliance to the TRIPS 
regulations at the time of research. 
Compliance with TRIPS would 
improve the outlook for more 
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technologically intensive activities. In 
fact, the research findings support this 
concept. Most investment was 
anticipated in the area of sales and 
marketing activities, manufacturing 
and, to a certain degree, in clinical 
trials. During the workshops it became 
evident that clinical trials were 
envisaged to provide an improved 
commercialization potential rather than 
to serve primarily scientific purposes. 
The relatively low factor conditions, 
particularly in scientific disciplines, 
have to be considered as underlying 
reasons based on the focus group 
interviews. The strong 
commercialization focus becomes 
evident when considering the results on 
alliances.  
However, clinical trials are likely 
to spark the transfer of scientific skills 
and the development of scientific 
conditions. Positive impacts on local 
researchers and institutions can be 
expected.  It needs to be reiterated that 
IPR fulfils important functions by 
reducing future risk and increasing 
revenue expectations, thus increasing 
the NPV of investment projects. IPR in 
interaction with other change driver is 
expected to enhance a country’s factor 
condition development. The investment 
in technological areas is expected to 
gradually induce to technology transfer. 
It was demonstrated that the time factor 
plays an important role for the 
implications of IPR. The implications 
appear to be more long-term related 
(meaning beyond 5 years). The long-
term research and development cycles 
in this industry appear to be relevant 
explanations in this context. 
10 Conclusion 
The findings demonstrate that it 
will take some time until substantial 
investment can be stimulated by TRIPS 
within the context of the international 
pharmaceutical industry. However, the 
erosion of the market share of copy 
products will take some time as well, 
due to the necessary availability of 
Indonesian patents.  In a way, this will 
be a rather balanced scenario until the 
benefits derived from innovation and 
investment clearly outweigh the 
economic downsides from limiting 
imitations for a developing country. 
Pipeline protection would be 
expected to accelerate the stimulation 
of investment and innovation.  
Moreover, the research findings 
support the rationalization of the 
argumentation on the economic 
dimension of patented drugs in 
Indonesia.  
These economic dimensions clearly 
indicate that significant economic 
benefits of IPR are mostly related to the 
long-term future. In a way these 
findings suggest that TRIPS allows 
significant time of adjusting an 
economy from imitation to innovation 
and to buffer negative implications on 
local industry. 
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